Trastuzumab after primary treatment for early stage HER2-positive breast cancer reduces recurrence

Cancer Treatment Reviews

Volumn 32, Issue 2, 2006, Pages 144-148

  Dent, Rebecca ^a   Clemons, Mark ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; TAMOXIFEN; TRASTUZUMAB;

BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEALTH CARE ACCESS; HEART INJURY; HUMAN; SHORT SURVEY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 33644848237     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2006.01.005     Document Type: Note

References (7)

1. D.J. Slamon G.M. Clark S.G. Wong W.J. Levin A. Ullrich W.L. McGuire Human breast cancer: Correlation of relapse and survival with amplification of the HER2/neu oncogene Science 235 1987 177-182
2. D.J. Slamon B. Leyland-Jones S. Shak et. al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783-792
3. E.H. Romond E.A. Perez J. Bryant et. al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 2005 1673-1684
4. M.J. Piccart-Gebhart M. Procter B. Leyland-Jones et. al. Trastuzumab after adjuvant chemotherapy in HER2 positive breast cancer N Engl J Med 353 2005 1659-1672
5. Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cycyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TC) in HER2 positive early breast cancer patients: BCIRG 006 study. In: Program and abstracts of the 28th annual San Antonio breast cancer symposium, December 8-11, San Antonio, TX; 2005 [Abstract 1].
6. M.N. Levine Trastuzumab cardiac side effects: Only time will tell J Clin Oncol 23 2005 7775-7776
7. Joensuu H, Kellokumpu-Lehtinen P-L, Bono P, et al. Trastuzumab in combination with docetaxel or vinorelbine as adjuvant treatment of breast cancer: The FinHer Trial. In Program and abstracts of the 28th annual San Antonio breast cancer symposium, December 8-11, San Antonio, TX; 2005 [Abstract 2].